Research ArticleNeurology
Validation of Noninvasive Tracer Kinetic Analysis of 18F-Florbetaben PET Using a Dual–Time-Window Acquisition Protocol
Santiago Bullich, Henryk Barthel, Norman Koglin, Georg A. Becker, Susan De Santi, Aleksandar Jovalekic, Andrew W. Stephens and Osama Sabri
Journal of Nuclear Medicine July 2018, 59 (7) 1104-1110; DOI: https://doi.org/10.2967/jnumed.117.200964
Santiago Bullich
1Piramal Imaging GmbH, Berlin, Germany
Henryk Barthel
2Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany; and
Norman Koglin
1Piramal Imaging GmbH, Berlin, Germany
Georg A. Becker
2Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany; and
Susan De Santi
3Piramal Pharma Inc., Boston, Massachusetts
Aleksandar Jovalekic
1Piramal Imaging GmbH, Berlin, Germany
Andrew W. Stephens
1Piramal Imaging GmbH, Berlin, Germany
Osama Sabri
2Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany; and

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 59, Issue 7
July 1, 2018
Validation of Noninvasive Tracer Kinetic Analysis of 18F-Florbetaben PET Using a Dual–Time-Window Acquisition Protocol
Santiago Bullich, Henryk Barthel, Norman Koglin, Georg A. Becker, Susan De Santi, Aleksandar Jovalekic, Andrew W. Stephens, Osama Sabri
Journal of Nuclear Medicine Jul 2018, 59 (7) 1104-1110; DOI: 10.2967/jnumed.117.200964
Validation of Noninvasive Tracer Kinetic Analysis of 18F-Florbetaben PET Using a Dual–Time-Window Acquisition Protocol
Santiago Bullich, Henryk Barthel, Norman Koglin, Georg A. Becker, Susan De Santi, Aleksandar Jovalekic, Andrew W. Stephens, Osama Sabri
Journal of Nuclear Medicine Jul 2018, 59 (7) 1104-1110; DOI: 10.2967/jnumed.117.200964
Jump to section
Related Articles
Cited By...
- Early-Frame [18F]Florbetaben PET/MRI for Cerebral Blood Flow Quantification in Patients with Cognitive Impairment: Comparison to an [15O]Water Gold Standard
- The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid Quantification
- Determining Amyloid-{beta} Positivity Using 18F-AZD4694 PET Imaging
- Exploiting the Full Potential of {beta}-Amyloid and Tau PET Imaging for Drug Efficacy Testing